Efficacy of Immune Checkpoint Inhibitors with Chemotherapy in Pulmonary Sarcomatoid Carcinoma

Researchers at the Department of Medical Oncology conducted an open-label, single-arm Phase II trial to evaluate the effectiveness and safety profile of first-line immune checkpoint inhibitors combined with chemotherapy in pulmonary sarcomatoid carcinoma (PSC). The study found that the combination of immune checkpoint inhibitors with chemotherapy showed robust efficacy alongside acceptable toxicity in advanced-stage PSC. This innovative treatment approach has the potential to improve clinical outcomes for patients with this rare and aggressive subtype of non-small cell lung cancer.

Key Takeaways:

• The study enrolled 38 patients with a predominantly male population (91%, n=34) with a median age of 65.4 years, and 86.8% (n=33) had smoking histories.
• The primary endpoint was objective response rate (ORR), with a result of 73.7%, and the secondary endpoint of disease control rate (DCR) was 94.7%.
• The median progression-free survival (PFS) was 13.3 months (95% CI, 10.2-15.7), and the median overall survival (OS) was not reached.
• The most common immune-related adverse events were pneumonitis, with an incidence of 13.2%, and the majority of observed adverse events were grades 1 or 2.
• The study concluded that immune checkpoint inhibitors combined with chemotherapy could be a better option for PSC.

Statistics:

• 38 patients were enrolled in the study.
• 91% of patients were male (n=34).
• The median age of patients was 65.4 years.
• 86.8% of patients had smoking histories (n=33).
• The ORR was 73.7%.
• The DCR was 94.7%.
• The median PFS was 13.3 months (95% CI, 10.2-15.7).
• The median OS was not reached.
• The incidence of pneumonitis was 13.2%.

Sources:

• Evaluation of the Effectiveness and Safety Profile of First-Line Immune Checkpoint Inhibitors Combined with Chemotherapy in Pulmonary Sarcomatoid Carcinoma. Lung Cancer: Targets and Therapy, 2025, Volume 16, Issue 1: 73-83.